BlackRock Health Sciences Trust II
BMEZ · NYSE
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | -0.25 | 0.00 |
| FCF Yield | 41.34% | -6.23% | -0.86% | 2.84% |
| EV / EBITDA | -8.50 | 4.69 | 23.46 | 20.24 |
| Quality | ||||
| ROIC | -5.63% | 7.34% | 1.46% | 1.86% |
| Gross Margin | 112.62% | 903.99% | 83.50% | 81.92% |
| Cash Conversion Ratio | -1.15 | -0.15 | -0.20 | 0.58 |
| Growth | ||||
| Revenue 3-Year CAGR | 3,892,183.76% | 3,255,688.25% | 3,267,714.60% | 2,551,121.41% |
| Free Cash Flow Growth | 689.39% | -665.45% | -126.85% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.01 | 0.02 | 0.01 | -0.00 |
| Interest Coverage | -577,516.69 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 4.40 | -746.44 | 7.76 | 5.80 |